Market Place
Sourcing Support
FDA approves J&J`s ketamine-derived depression treatment
22 Jan 2025 //
PRESS RELEASE
Enforcement Report - Week of January 8, 2025
08 Jan 2025 //
FDA
HOPE, NRx Pharma Experts To Present On PTSD & Depression Treatment
07 Jan 2025 //
PR NEWSWIRE
PharmaTher Updates on FDA NDA for Ketamine
26 Nov 2024 //
GLOBENEWSWIRE
PharmaTher Updates on FDA NDA for Ketamine
19 Nov 2024 //
GLOBENEWSWIRE
NRX-100 (Ketamine) Reaches Stability Milestone
30 Sep 2024 //
CONTRACT PHARMA
Ketabon To Present At-Home Ketamine Therapy At ECNP 2024
18 Sep 2024 //
GLOBENEWSWIRE
PharmaTher Announces Update on FDA NDA for Ketamine
04 Sep 2024 //
GLOBENEWSWIRE
Psychemedics Corporation Launches New Ketamine Hair Testing Service
29 Aug 2024 //
GLOBENEWSWIRE
SciSparc-Clearmind Ketamine-Based Combination Patent Application Published
29 Aug 2024 //
GLOBENEWSWIRE
MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile
24 Jun 2024 //
PR NEWSWIRE
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
10 Jun 2024 //
PR NEWSWIRE
NRx Chairman Dr. Javitt to Present at the Ketamine 2024 Conference UK
25 Mar 2024 //
PR NEWSWIRE
Ketamine ER by Douglas Pharmaceuticals for Major Depressive Disorder: Likelihood of Approval
30 Aug 2023 //
PHARMACEUTICAL-TECHNOLOGY
PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX
27 Jun 2023 //
GLOBENEWSWIRE
Enforcement Report - Week of May 24, 2023
24 May 2023 //
FDA
Juno Pharmaceuticals Approved to Import Ketamine, Providing Immediate Relief =
04 May 2023 //
BUSINESSWIRE
Fresenius` Generic Ketamine Hydrochloride Receives Approval in the U.S.
13 Jan 2023 //
FDA
Melt Pharmaceuticals’ MELT-300 Achieves Primary Sedation Endpoint
21 Dec 2022 //
BUSINESSWIRE
PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine
15 Dec 2022 //
GLOBENEWSWIRE
PharmaTher Announces Poster Presentation +ve Efficacy & Safety Data from Ph1/2
14 Nov 2022 //
GLOBENEWSWIRE
Stigma in drug research holding back new therapies
10 Oct 2022 //
ECONOMIC TIMES
Drugs Effects of Ketamine in Mice can Depend on the Sex of the Human
30 Aug 2022 //
NEUROSCIENCENEWS
Ketamine Ushering in Pharmacology Therapies for Neurological Disorders
27 Jul 2022 //
PRNEWSWIRE
PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine
13 Jul 2022 //
GLOBENEWSWIRE
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch
29 Jun 2022 //
GLOBENEWSWIRE
First patient dosed in second Phase 2 add-on Ketamine Trial in TRD
08 Jun 2022 //
GLOBENEWSWIRE
Enforcement Report - Week of June 8, 2022
08 Jun 2022 //
FDA
PharmaTher grows ketamine portfolio with on-body injector deal
27 May 2022 //
FIERCEPHARMA
Prolonged-release ketamine advances after COVID-disrupted trial
06 Apr 2022 //
FIERCEPHARMA
Revitalist and PharmaTher Collaborate for Ketamine Treatment Protocols
01 Mar 2022 //
BUSINESSWIRE
Braxia Provides Update on Large Proprietary Dataset for Ketamine and Psilocybin
31 Jan 2022 //
PRNEWSWIRE
atai Life Sciences announces FDA IND Clearance for PCN-101 R-ketamine Program
12 Jan 2022 //
GLOBENEWSWIRE
PharmaTher Announces FDA Approval of IND Application for Ketamine to Treat ALS
12 Jan 2022 //
GLOBENEWSWIRE
Drug Treatment Delivery Model with Inherently Unfavorable Risk-Benefit Profile
11 Jan 2022 //
PRNEWSWIRE
Osmind to Publish Analysis of Ketamine Infusion Therapy for Depression
11 Jan 2022 //
BUSINESSWIRE
Melt Pharmaceuticals Submits INDs for MELT?210 and MELT-400 to FDA
04 Jan 2022 //
BUSINESSWIRE
University of Exeter: Ketamine Treats Symptoms of Depression, Suicidal Thoughts
03 Jan 2022 //
TRIALSITENEWS
PharmaTher Enters Into Process Development Agreement With LTS LOHMANN
20 Dec 2021 //
GLOBENEWSWIRE
PharmaTher Applies for FDA ODD for Ketamine in Status Epilepticus
24 Nov 2021 //
GLOBENEWSWIRE
Seelos Acquires Exc. License of iX Biopharma`s Wafer-Based Delivery Platform
24 Nov 2021 //
PRNEWSWIRE
Bexson Announces Expansion to Treat Major Depression with Wearable Ketamine
18 Nov 2021 //
PRNEWSWIRE
Braxia Announces Voting Results from Annual General Meeting of Shareholders
29 Oct 2021 //
PRNEWSWIRE
Ketamine`s Potential As A Treatment For Depression Has Drawn Major Industry
27 Oct 2021 //
PRNEWSWIRE
Cybin Announces FDA IND Authorization of Sponsored Feasibility Study
26 Oct 2021 //
BUSINESSWIRE
FDA warns Minnesota doc for running trials without INDs
19 Oct 2021 //
ENDPTS
PharmaTher Engages Alcami for Clinical and Commercial MFG of Novel Ketamine
19 Oct 2021 //
GLOBENEWSWIRE
Ketamine One Launching Two Inaugural Research Studies
14 Oct 2021 //
GLOBENEWSWIRE
Braxia Scientific Reports Encouraging Results of Ketamine Study
30 Sep 2021 //
PRNEWSWIRE
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine)
14 Sep 2021 //
GLOBENEWSWIRE
AIkido Pharma Files Patent Application for the Use of Ketamine
23 Jun 2021 //
PRNEWSWIRE
PharmaTher Provides Research and Development Update and Milestones for 2021
10 Jun 2021 //
GLOBENEWSWIRE
PharmaTher Expands Patent Portfolio with Filing of U.S. Patent for Ketamine
27 Apr 2021 //
GLOBENEWSWIRE
Seelos Announces Completion of Open-Label Patient Enrollment Study of SLS-002
05 Mar 2021 //
PRNEWSWIRE
Core One Labs Finalizes Deal to Acquire Ketamine Infusions Centers of Texas
24 Feb 2021 //
BIOSPACE
Seelos Announces Dosing of the First Patients in a Study of SLS-002
15 Jan 2021 //
PRNEWSWIRE
Repeated Ketamine Infusions Reduce Symptom Severity in Individuals With Chronic
05 Jan 2021 //
NEWSWISE
Seelos Therapeutics Announces Final Data from Phase I PK/PD Study
23 Jun 2020 //
GLOBENEWSWIRE
Champignon Provides Corporate Update; Announces Name Change, Rebranding
12 Jun 2020 //
GLOBENEWSWIRE
